Baker Brothers Advisors
| Company type | Private |
|---|---|
| Industry | Hedge fund management, Biotechnology investments |
| Founded | 2000 |
| Founder | Felix Baker, Julian Baker |
| Headquarters | New York , United States |
| Products | Hedge fund management |
Baker Brothers Advisors (BBA) is an American hedge fund management firm headquartered in New York, specializing in investments within the biotechnology sector. The firm oversees assets exceeding $20 billion in total assets under management (AUM).
Background
Established in 2000 by siblings Felix and Julian Baker, BBA benefits from their diverse backgrounds: Felix possesses a B.S. in biology, a Ph.D. in immunology, and has attended medical school, whereas Julian earned a B.A. in social studies from Harvard University and has experience in private equity at Credit Suisse First Boston. Prior to founding BBA, the brothers handled healthcare investment portfolios for the Laurence Tisch family, proprietors of Loews Corporation.
BBA maintained strong connections with the Tisch family and operated out of 667 Madison Avenue—the same address as Loews—up until 2017. The firm is recognized for its low profile, lacking an official website and deliberately avoiding media exposure to preserve confidentiality regarding its investment methodologies.
Investment strategy
Concentrating its efforts on biotechnology, BBA has built a reputation for delivering robust returns. For instance, Yale University’s endowment held $274 million invested with BBA in 2009, which expanded to $1.08 billion by 2016 through additional capital contributions and $393 million in profits. In a notable event during October 2019, BBA’s portfolio value increased by $1.4 billion within two weeks, primarily driven by holdings in Seagen and BeiGene. According to an August 2024 report by The Wall Street Journal, BBA’s 25% ownership stake in Seagen since 2003 generated an $8 billion gain when Pfizer acquired Seagen for $43 billion in 2023—marking one of the highest capital return achievements in the biotechnology field. The majority of these profits were distributed back to investors as BBA found limited avenues to deploy all available capital concurrently.
The firm's accomplishments are attributed to breakthroughs in genetics, rising valuations of biotech equities, and consolidation trends where major biopharmaceutical companies acquire smaller innovators. BBA frequently recruits executives and scientists from its portfolio companies and often places them on boards across its investments. By 2019, eight out of BBA’s top twenty public company holdings included at least one board member affiliated with BBA; additionally, seven CEOs also held board positions at other companies supported by the firm. While some industry figures like Eve Slater commend BBA’s "scientifically driven" and "engaged" board representatives, others such as RA Capital Management have criticized BBA's influence—highlighting instances like the blocked merger between BioCryst Pharmaceuticals and Idera Pharmaceuticals where BBA was perceived as prioritizing its own interests over those of other shareholders.